Chugai Pharma USA, Inc.

Emerging Company in the Spotlight sponsored by JFK Communications.

Congratulations to Chugai Pharma USA, Inc. BioNJ’s Emerging Company in the Spotlight for December. Each month we will feature a BioNJ Member who is progressively growing and evolving within the New Jersey biotechnology industry. So many of our Members are making a dramatic impact on our State’s innovative ecosystem. And, for that we say thank you and congratulations. We celebrate you!

Chugai Pharma USA, Inc. (CPUSA), headquartered in Berkeley Heights, NJ, is a wholly owned subsidiary of Tokyo-based Chugai Pharmaceutical Co., Ltd., a member of the Roche Group. CPUSA is a rapidly growing company that supports the planning and execution of global clinical programs for innovative new drug candidates originated by the parent company, Chugai. CPUSA specializes in early clinical development of Chugai pipeline products and aims to accelerate proof-of-concept for rapid shift to global development.

CPUSA, part of Chugai’s global Translational Clinical Research Division (TCRD), has completed early stage development of Alecensa® (alectinib) and GC33 in the U.S., both of which have been out-licensed to Roche. CPUSA currently has the following three ongoing development programs, where Chugai is independently pursuing global development of its original products:

  • SA237, anti-IL-6 receptor monoclonal antibody applied with recycling antibody technology (Chugai’s proprietary antibody engineering technology) for neuromyelitis optica (Phase III)
  • CIM331, anti-IL-31 receptor monoclonal antibody for atopic dermatitis (Phase II)
  • PCO371, PTH1 receptor agonist for hypoparathyroidism (Phase I)

Chugai is one of Japan’s leading research-based pharmaceutical companies with strengths in biotechnology. Specializing in prescription pharmaceuticals, Chugai is working to develop innovative products with global applications in the fields of oncology, bone and joint diseases, and renal diseases, as well as other therapeutic areas with unmet medical needs. The company develops its products independently from Roche until early proof-of-concept for worldwide market. For late stage clinical development and marketing outside of Japan, South Korea and Taiwan, Chugai seeks partnership with Roche or other third-party companies.

“It is in our culture at CPUSA to be driven by the need to serve patients, and ultimately improve the lives of those suffering from treatable illnesses,” said Athos Gianella-Borradori, M.D., chief medical officer at CPUSA. “We have a strong development program and we will continue to innovate with Chugai in a mutual global effort to deliver first- and best-in-class products and services for patient benefit.”

As long-time members of the New Jersey biotechnology ecosystem, CPUSA has recently renovated its headquarters to not only accommodate a growing team, but also to inspire innovation and foster a collaborative culture. On November 20, 2015, CPUSA honored the grand reopening of its Berkley Heights location with a ribbon-cutting ceremony.

For more information on Chugai Pharma USA, Inc., visit www.chugai-pharm.com, or contact the Communications Group.